Overview

Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With St

Status:
Completed

Trial end date:
2014-03-01

Target enrollment:

Participant gender:

Summary

This study is an exploratory Phase 1 randomized, double-blind (Investigator and study subject and 2-D echo endpoint assessor), placebo-controlled single IV infusion dose escalation study that will enroll up to approximately 32 subjects with stage 1 or 2 essential hypertension.

Phase:

Phase 1

Details

Lead Sponsor:

PhaseBio Pharmaceuticals Inc.

Treatments:

VIP-ELP fusion molecule PB1046